Cargando…

Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers

The nitric oxide synthase (NOS) pathway has been clearly demonstrated to regulate angiogenesis. Increased levels of NO correlate with tumour growth and spreading in different experimental and human cancers. Drugs interfering with the NOS pathway may be useful in angiogenesis-dependent tumours. The a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morbidelli, L, Donnini, S, Filippi, S, Messori, L, Piccioli, F, Orioli, P, Sava, G, Ziche, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741040/ https://www.ncbi.nlm.nih.gov/pubmed/12778081 http://dx.doi.org/10.1038/sj.bjc.6600906

Ejemplares similares

Binding of Antitumor Ruthenium(III) Complexes to Plasma Proteins
por: Messori, L., et al.
Publicado: (2000)

Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents
por: Morbidelli, Lucia, et al.
Publicado: (2016)

Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties
por: Castellarin, Anna, et al.
Publicado: (2016)

Uncovering Knowledge Gaps in the Safety Profile of Antiangiogenic Drugs in Cancer Patients: Insights from Spontaneous Reporting Systems Studies
por: Ciccone, Valerio, et al.
Publicado: (2023)

Endothelial Aldehyde Dehydrogenase 2 as a Target to Maintain Vascular Wellness and Function in Ageing
por: Nannelli, Ginevra, et al.
Publicado: (2020)

How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance
por: Ciccone, Valerio, et al.
Publicado: (2020)

Antiangiogenic activity of aplidine, a new agent of marine origin
por: Taraboletti, G, et al.
Publicado: (2004)

Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants.
por: Ziche, M., et al.
Publicado: (1998)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Monitoring Endothelial and Tissue Responses to Cobalt Ferrite Nanoparticles and Hybrid Hydrogels
por: Finetti, Federica, et al.
Publicado: (2016)

Involvement of Bradykinin B2 Receptor in Pathological Vascularization in Oxygen-Induced Retinopathy in Mice and Rabbit Cornea
por: Terzuoli, Erika, et al.
Publicado: (2018)

Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells
por: Ciccone, Valerio, et al.
Publicado: (2018)

Correction to: Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells
por: Ciccone, Valerio, et al.
Publicado: (2019)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

Gold(III) Compounds as New Family of Anticancer Drugs
por: Messori, Luigi, et al.
Publicado: (2003)

ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL-8/Notch signaling cascade
por: Ciccone, Valerio, et al.
Publicado: (2022)

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
por: Zeisberger, S M, et al.
Publicado: (2006)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

Some Prescriptions Discussed—III
Publicado: (1910)

Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion
por: Siegert, A, et al.
Publicado: (2002)

Secret Remedies and Branded Products—III
Publicado: (1908)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

NF-κB inhibition impairs the radioresponse of hypoxic EMT-6 tumour cells through downregulation of inducible nitric oxide synthase
por: Ridder, M De, et al.
Publicado: (2003)

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft
por: Petrangolini, G, et al.
Publicado: (2004)

ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output
por: Terzuoli, Erika, et al.
Publicado: (2019)

Nitric Oxide Transport in Normal Human Thoracic Aorta: Effects of Hemodynamics and Nitric Oxide Scavengers
por: Liu, Xiao, et al.
Publicado: (2014)

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer
por: Aird, R E, et al.
Publicado: (2002)

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
por: Awasthi, Niranjan, et al.
Publicado: (2022)

Biological Properties of IRIM, the Iridium(III) Analogue of (Imidazolium (Bisimidazole) Tetrachlororuthenate) (ICR)
por: Marcon, G., et al.
Publicado: (2000)

17β-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response
por: Chinje, E C, et al.
Publicado: (2002)

In vivo experimental evidence that the nitric oxide pathway is involved in the X-ray-induced antiangiogenicity.
por: Hatjikondi, O., et al.
Publicado: (1996)

Water-Soluble Ruthenium(III)-Dimethyl Sulfoxide Complexes: Chemical Behaviour and Pharmaceutical Properties
por: Mestroni, G., et al.
Publicado: (1994)

Enhanced Vascular Permeability in Solid Tumor Is Mediated by Nitric Oxide and Inhibited by Both New Nitric Oxide Scavenger and Nitric Oxide Synthase Inhibitor
por: Maeda, Hiroshi, et al.
Publicado: (1994)

A Novel Ruthenium-based Molecular Sensor to Detect Endothelial Nitric Oxide
por: Vidanapathirana, Achini K., et al.
Publicado: (2019)

Comparison of the Antiproliferative Activity of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin and Transferrin-Bound Forms in a Human Colon Cancer Cell Line
por: Kratz, F., et al.
Publicado: (1996)

Non-symbiotic haemoglobins—What's happening beyond nitric oxide scavenging?
por: Hill, Robert D.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3irt0q3cr80aomkb1vgmj3m631